While the presence of these variants has no impact on AD risk levels (Table 2) in three cohorts (ADNI, MAYO, DBCBB), they significantly affect protein concentrations of SERPINE1 in the PREVENT-AD and ADNI cohorts and the mRNA levels in the MAYO cohort. This evidence concerns the gene SERPINE1 and Alzheimer disease.